Julien Cherfils-Vicini
Overview
Explore the profile of Julien Cherfils-Vicini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iltis C, Moskalevska I, Debiesse A, Seguin L, Fissoun C, Cervera L, et al.
Nat Aging
. 2024 Dec;
5(2):219-236.
PMID: 39730825
Although senescent cells can be eliminated by the immune system, they tend to accumulate with age in various tissues. Here we show that senescent cells can evade immune clearance by...
2.
Kellermann G, Leulliot N, Cherfils-Vicini J, Blaud M, Brest P
Front Immunol
. 2024 Apr;
15:1382236.
PMID: 38571942
Immune checkpoint therapies (ICT) have transformed the treatment of cancer over the past decade. However, many patients do not respond or suffer relapses. Successful immunotherapy requires epitope spreading, but the...
3.
Mousset A, Lecorgne E, Bourget I, Lopez P, Jenovai K, Cherfils-Vicini J, et al.
Cancer Cell
. 2023 Apr;
41(4):757-775.e10.
PMID: 37037615
Metastasis is the major cause of cancer death, and the development of therapy resistance is common. The tumor microenvironment can confer chemotherapy resistance (chemoresistance), but little is known about how...
4.
El Mai M, Janho Dit Hreich S, Gaggioli C, Roisin A, Wagner N, Ye J, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34203903
Telomeric repeat-binding factor 2 (TRF2) is a subunit of the shelterin protein complex, which binds to and protects telomeres from unwanted DNA damage response (DDR) activation. TRF2 expression plays a...
5.
Jacome Burbano M, Cherfils-Vicini J, Gilson E
EMBO J
. 2021 Apr;
40(9):e108164.
PMID: 33880795
Cellular senescence is considered to be a major driver of aging, yet the mechanisms explaining the accumulation of senescent cells during life time remain unclear. In this issue, Lagnado et...
6.
Ilie M, Lanteri E, Chamorey E, Thamphya B, Hamila M, Montaudie H, et al.
Oncoimmunology
. 2021 Apr;
10(1):1901446.
PMID: 33796413
The outcome of patients with cutaneous melanoma has been strongly modified by recent advances obtained with Immune Checkpoint Inhibitors (ICIs). However, despite this breakthrough, durable response to ICIs is limited...
7.
Douguet L, Janho Dit Hreich S, Benzaquen J, Seguin L, Juhel T, Dezitter X, et al.
Nat Commun
. 2021 Jan;
12(1):653.
PMID: 33510147
Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome. We develop a chemical positive...
8.
Cherfils-Vicini J, Gilson E
Med Sci (Paris)
. 2020 Dec;
36(12):1113-1117.
PMID: 33296627
Aging is an alteration of our physiological capacities that is accompanied by an increased susceptibility to develop a wide range of diseases and which determines in large part our longevity....
9.
Cherfils-Vicini J, Gilson E
EMBO Mol Med
. 2019 Jul;
11(7):e10845.
PMID: 31273935
In the context of tumorigenesis, telomere shortening is associated with apparent antagonistic outcomes: On one side, it favors cancer initiation through mechanisms involving genome instability, while on the other side,...
10.
Cherfils-Vicini J, Iltis C, Cervera L, Pisano S, Croce O, Sadouni N, et al.
EMBO J
. 2019 Apr;
38(11).
PMID: 31000523
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells with strong immunosuppressive activity that promote tumor growth. In this study, we describe a mechanism by which cancer cells control MDSCs in...